Home » Topics » BioWorld Science

BioWorld Science
RSS

Celgene presents results from two phase I studies of CC-90002

Dec. 24, 2019

Phase I study of mutant EGFR inhibitor TQB-3804 begins

Dec. 24, 2019

PET imaging agent PyL meets primary endpoint in phase III prostate cancer trial

Dec. 24, 2019

Phase II study begins for URO-902 in overactive bladder

Dec. 24, 2019

Trial to evaluate Trevena's TRV-734 for opioid use disorder

Dec. 24, 2019

Lumateperone approved in the U.S. for schizophrenia

Dec. 24, 2019

Interim data from gene therapy trial confirm BCL11A as therapeutic target in SCD

Dec. 24, 2019

IL-1beta as a promising new biomarker in treatment-resistant bipolar depression

Dec. 24, 2019

Gilead evaluates GS-6207 with other antiretrovirals for HIV in new phase II study

Dec. 24, 2019

Jazz Pharmaceuticals enrolling patients in phase II/III study of JZP-458 for ALL/LBL

Dec. 24, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...